LivaNova (NASDAQ:LIVN) Updates FY 2026 Earnings Guidance

LivaNova (NASDAQ:LIVN) updated its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 4.300-4.400 for the period, compared to the consensus estimate of 4.150. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

LivaNova Trading Up 3.5%

Shares of NASDAQ LIVN opened at $85.32 on Wednesday. LivaNova has a 12-month low of $41.87 and a 12-month high of $85.76. The company has a market cap of $4.69 billion, a price-to-earnings ratio of 43.75 and a beta of 0.86. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24. The stock’s 50 day simple moving average is $79.46 and its 200 day simple moving average is $70.51.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $1.26 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.17. The firm had revenue of $390.54 million during the quarter, compared to the consensus estimate of $380.50 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.LivaNova has set its FY 2026 guidance at 4.300-4.400 EPS. Equities research analysts expect that LivaNova will post 3.73 EPS for the current year.

Wall Street Analysts Forecast Growth

LIVN has been the topic of several recent research reports. Mizuho lifted their price objective on shares of LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. KeyCorp boosted their price objective on LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, June 22nd. Robert W. Baird lowered their target price on LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Barclays lifted their target price on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Finally, Weiss Ratings raised LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $81.38.

Insider Activity at LivaNova

In related news, Director Francesco Bianchi sold 1,800 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the sale, the director owned 7,228 shares of the company’s stock, valued at $547,521. The trade was a 19.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.35% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On LivaNova

A number of institutional investors and hedge funds have recently bought and sold shares of the business. State of Wyoming acquired a new position in shares of LivaNova in the 2nd quarter worth approximately $31,000. EverSource Wealth Advisors LLC boosted its holdings in LivaNova by 998.4% during the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after buying an additional 639 shares in the last quarter. Quarry LP acquired a new position in LivaNova in the third quarter worth approximately $36,000. UMB Bank n.a. increased its holdings in shares of LivaNova by 22.6% in the fourth quarter. UMB Bank n.a. now owns 971 shares of the company’s stock valued at $60,000 after buying an additional 179 shares in the last quarter. Finally, Johnson Financial Group Inc. bought a new position in shares of LivaNova in the third quarter valued at $63,000. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.